<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001053</url>
  </required_header>
  <id_info>
    <org_study_id>AVEG 019</org_study_id>
    <secondary_id>10569</secondary_id>
    <nct_id>NCT00001053</nct_id>
  </id_info>
  <brief_title>A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects</brief_title>
  <official_title>A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and immunogenicity of HIV p17/p24:Ty-VLP (virus-like particles)&#xD;
      vaccine in uninfected volunteers. Specifically, to determine whether the vaccine formulated&#xD;
      with and without alum induces CD8+ cytotoxic T lymphocytes ( CTLs ) that may be&#xD;
      cross-reactive against multiple HIV-1 stains. Also, to determine whether boosting with the&#xD;
      vaccine orally or rectally will help induce mucosal antibody responses.&#xD;
&#xD;
      Induction of CD8+ CTL activity is considered a critical property for a candidate vaccine.&#xD;
      Additionally, since the majority of HIV-1 infections occur after inoculation of a mucosal&#xD;
      surface, it is desirable to induce mucosal immunity as well as systemic immunity. The HIV&#xD;
      p17/p24:Ty-VLP vaccine may potentially induce both CTL and mucosal antibody responses against&#xD;
      HIV-1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of CD8+ CTL activity is considered a critical property for a candidate vaccine.&#xD;
      Additionally, since the majority of HIV-1 infections occur after inoculation of a mucosal&#xD;
      surface, it is desirable to induce mucosal immunity as well as systemic immunity. The HIV&#xD;
      p17/p24:Ty-VLP vaccine may potentially induce both CTL and mucosal antibody responses against&#xD;
      HIV-1.&#xD;
&#xD;
      Volunteers receive HIV p17/p24:Ty-VLP vaccine or placebo by IM injection (with or without&#xD;
      alum adjuvant) at months 0, 2, and 6, and then either by mouth or rectal enema at months 10&#xD;
      and 11. Volunteers who receive oral vaccine boosting will receive concurrent omeprazole to&#xD;
      decrease stomach acid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 1996</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV p17/p24:Ty-VLP</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aluminum hydroxide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication: Required:&#xD;
&#xD;
          -  Omeprazole given concurrently in patients receiving the oral vaccine dose.&#xD;
&#xD;
        Volunteers must have:&#xD;
&#xD;
          -  HIV-1 negativity.&#xD;
&#xD;
          -  Normal history and physical exam.&#xD;
&#xD;
          -  Lower risk for HIV infection.&#xD;
&#xD;
          -  CD4 count &gt;= 400 cells/mm3.&#xD;
&#xD;
          -  Normal urine dipstick with esterase and nitrite.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  No more than 10 percent of volunteers may be over age 50.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Volunteers with the following conditions are excluded:&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen.&#xD;
&#xD;
          -  Medical or psychiatric condition (including recent suicidal ideation or present&#xD;
             psychosis) that precludes compliance.&#xD;
&#xD;
          -  Occupational responsibilities that preclude compliance.&#xD;
&#xD;
          -  Active syphilis (NOTE: If serology is documented to be a false positive or due to a&#xD;
             remote (&gt; 6 months) infection, subject is eligible).&#xD;
&#xD;
          -  Active tuberculosis (NOTE: Subjects with a positive PPD and normal x-ray showing no&#xD;
             evidence of TB and who do not require INH therapy are eligible).&#xD;
&#xD;
        Volunteers with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of immunodeficiency, chronic illness, malignancy, autoimmune disease, or use&#xD;
             of immunosuppressive medications.&#xD;
&#xD;
          -  History of cancer unless surgically excised with reasonable assurance of cure.&#xD;
&#xD;
          -  History of suicide attempts or past psychosis.&#xD;
&#xD;
          -  History of anaphylaxis or other serious adverse reactions to vaccines.&#xD;
&#xD;
          -  History of serious allergic reaction requiring hospitalization or emergent medical&#xD;
             care.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior HIV-1 vaccines or placebo in an HIV vaccine trial.&#xD;
&#xD;
          -  Live attenuated vaccines within the past 60 days. NOTE: Medically indicated subunit or&#xD;
             killed vaccines (e.g., influenza, pneumococcal) do not exclude but should be&#xD;
             administered at least 2 weeks prior to HIV immunizations.&#xD;
&#xD;
          -  Experimental agents within the past 30 days.&#xD;
&#xD;
        Prior Treatment: Excluded:&#xD;
&#xD;
          -  Blood products or immunoglobulin within the past 6 months.&#xD;
&#xD;
        Higher risk behavior for HIV infection as determined by screening questionnaire, including:&#xD;
&#xD;
          -  History of injection drug use within the past year.&#xD;
&#xD;
          -  Higher or intermediate risk sexual behavior.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spearman P</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Graham B</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Rochester AVEG</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martin SJ, Weber J, Roitt I, Matear P, Jones K, Vyakarnam A. Recombinant HIV-1 gag p24-Ty virus-like particles (VLP's) induce HIV-1 p24-specific T helper cells in seronegative volunteers vaccinated with these particles. Int Conf AIDS. 1992 Jul 19-24;8(2):A35 (abstract no PoA 2194)</citation>
  </reference>
  <reference>
    <citation>Weber J, Cheinsong-Popov R, Callow D, Adams S, Patou G, Hodgkin K, Martin S, Gotch F, Kingsman A. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine. 1995 Jun;13(9):831-4. doi: 10.1016/0264-410x(94)00061-q.</citation>
    <PMID>7483805</PMID>
  </reference>
  <reference>
    <citation>Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM, et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS. 1993 Oct;7(10):1315-23.</citation>
    <PMID>8267904</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>Recombinant Proteins</keyword>
  <keyword>HIV-1</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Core Protein p24</keyword>
  <keyword>p24-VLP vaccine</keyword>
  <keyword>Gene Products, gag</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

